摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

vincamine citrate | 1413535-10-0

中文名称
——
中文别名
——
英文名称
vincamine citrate
英文别名
2-hydroxypropane-1,2,3-tricarboxylic acid;methyl (15S,17S,19S)-15-ethyl-17-hydroxy-1,11-diazapentacyclo[9.6.2.02,7.08,18.015,19]nonadeca-2,4,6,8(18)-tetraene-17-carboxylate
vincamine citrate化学式
CAS
1413535-10-0
化学式
C6H8O7*C21H26N2O3
mdl
——
分子量
546.574
InChiKey
MVWVJXQYKPPROS-YAFGAGFVSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1.7
  • 重原子数:
    39
  • 可旋转键数:
    8
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.56
  • 拓扑面积:
    187
  • 氢给体数:
    5
  • 氢受体数:
    11

反应信息

  • 作为产物:
    描述:
    长春胺柠檬酸甲醇 为溶剂, 反应 0.75h, 生成 vincamine citrate
    参考文献:
    名称:
    Drug Salt Formation via Mechanochemistry: The Case Study of Vincamine
    摘要:
    In the present research a salt of vincamine, a poorly bioavailable indole alkaloid derived from the leaves of Vinca minor L., was synthesized in the solid state by means of a mechanochemical process employing citric acid as a reagent. The mechanochemical process was adopted as a solvent-free alternative to classical citrate synthetic route that involves the use of solvents. Since the mechanochemical salification is little studied to date and presents the disadvantage of offering a low yield, in this work, the influence of three process and formulation variables on the percentage of vincamine citrate was studied. In particular, the time of mechanical treatment (in planetary mill Fritsch P5) and the amount of citric acid were varied in order to evaluate their effect on the yield of the process, and the introduction of a solid solvent, a common pharmaceutical excipient (sodium carboxymethylcellulose, NaCMC), was considered. Due to the complexity of the resulting samples' matrix, an appropriate experimental design was employed to project the experimental trials and the influence of the three variables on the experimental response was estimated with the help of a statistical analysis. The experimental response, that is, the yield of the process corresponding to the percentage of vincamine in the protonated form, was unconventionally calculated by means of X-ray photoelectron spectroscopy analysis (XPS). Out of 16 samples, the one with the highest yield was the coground sample containing vincamine and citric acid in a 1:2 molar ratio, treated for 60 min in the presence of NaCMC. Under the above conditions the salification reaction was completed highlighting the importance of a proper selection of process and formulation variables of the mechanochemical salification, and emphasizing the crucial role of the solid solvent in facilitating the salification. The second step of the research encompassed the characterization of the citrate salt obtained by solid excipient assisted mechanochemical salification (SEAMS) in comparison with the vincamine citrate obtained by classical synthetic route. The samples were characterized by, besides XPS, high resolution transmission electron microscopy (HRTEM), X-ray powder diffraction (XRPD), in vitro solubilization kinetics and in vivo oral pilot study in rats. Finally, in order to monitor over time possible disproportionation phenomena, stability studies have been performed by repeating XPS analysis after 8 months. As expected, the the SEAMS-vincamine salt consisted of particles both crystalline and amorphous. The solubilization kinetics was superior to the corresponding salt probably thanks to the favorable presence of the hydrophilic excipient although the two salts were bioequivalent in rats after oral administration. Furthermore, no evidence of disporportionation phenomena in the SEAMS-vincamine salt was found after storage. In conclusion, in the case of forming salts of poorly soluble drugs, the SEAMS process may be an interesting alternative to both classical synthetic routes, eliminating the need for solvent removal, and simple neat mechanochemical salification, overcoming the problem of limited process yield.
    DOI:
    10.1021/mp300371f
点击查看最新优质反应信息

文献信息

  • US4362730A
    申请人:——
    公开号:US4362730A
    公开(公告)日:1982-12-07
查看更多

同类化合物

阿扑长春胺 长春醇 长春酸胺 长春西汀杂质O 长春西汀杂质N 长春西汀杂质L 长春西汀杂质K 长春西汀杂质J 长春西汀杂质I 长春西汀杂质27 长春西汀杂质22 长春西汀杂质1 长春西汀杂质 A 长春西汀 长春胺杂质 长春胺杂质 长春胺乙酯 长春胺 长春泊林 长春布宁 长春倍酯 长春乙酯羧酸 辛酸氨基甲酸乙酯N-氧化物 象牙酮宁 溴长春胺 富马酸溴长春胺 埃那胺 7-氨基-4-羟基-3-(苯偶氮基)萘-2-磺基酸 14,15-二氢阿扑长春胺乙酯 13alpha-乙基-2,3,5,6,13a,13b-六氢-1H-吲哚并(3,2,1-去)吡啶并(3,2,1-ij)(1,5)-萘啶-12-羧酸甲氧基甲基酯 (3alpha,16alpha)-6-羟基-象牙洪达木烯宁-14(15H)-酮 (3alpha,14beta,16alpha)-14,15-二氢-14-羟基埃那美宁-14-甲醇 (3-alpha,16-alpha)-象牙仔榄树宁-14-羧酸,苯并[c]呋喃酮基酯,盐酸盐 (+)-(14beta)-二氢长春西丁 Ethyl-10-brom-apovincamin-methansulfonat 14,15-Dehydro-21-epi-homo-eburnamonin (S)-11a-Ethyl-2,3,5,11,11a,11b-hexahydro-1H,4H-3a,9b-diaza-benzo[cd]fluoranthen-10-one; compound with 2-acetoxy-benzoic acid (S)-11a-Ethyl-2,3,5,11,11a,11b-hexahydro-1H,4H-3a,9b-diaza-benzo[cd]fluoranthen-10-one; compound with 3,5-dihydroxy-benzoic acid (S)-11a-Ethyl-2,3,5,11,11a,11b-hexahydro-1H,4H-3a,9b-diaza-benzo[cd]fluoranthen-10-one; compound with 2,4-dihydroxy-benzoic acid Vincinsaeure-β-Hydroxy-ethylester 2,3-Dihydroxy-propyl-16,17-dihydro-apovincaminat (S)-11a-Ethyl-2,3,5,11,11a,11b-hexahydro-1H,4H-3a,9b-diaza-benzo[cd]fluoranthen-10-one; compound with 2-(4-chloro-phenoxy)-2-methyl-propionic acid eburnamenine-14-carboxylic acid pentachlorophenyl ester Δ14-vincinone (S)-11a-Ethyl-2,3,5,11,11a,11b-hexahydro-1H,4H-3a,9b-diaza-benzo[cd]fluoranthen-10-one; compound with 2,2-dimethyl-propionic acid 10-Brom-Δ14,15-apovincamin Apovincinsaeureethylester N-Cyclopentylapovincaminamid N-Monocyclohexylapovincaminamid Dodecanoic acid (11aR,11bR)-11a-ethyl-8-methoxy-2,3,4,5,11a,11b-hexahydro-1H-3a,9b-diaza-benzo[cd]fluoranthen-10-ylmethyl ester; compound with 2,3-dihydroxy-succinic acid